Effects of Qidi Tangshen Formulation in treating DKD patients with albuminuria

Effects of Qidi Tangshen Formulation in treating DKD patients with albuminuria and its effects on oxidative stress

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100046403

Enrollment

Unknown

Registered

2021-05-15

Start date

2021-05-10

Completion date

Unknown

Last updated

2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic nephropathy

Interventions

Group A:Qidi Tangshen Formulation

Group B:Placebo

Eligibility

Sex/Gender

All

Age

30 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. No limit to gender, aged 30 to 80 years; 2. Meet the diagnostic criteria of diabetic nephropathy, meet the diagnostic criteria of stage 1-2 chronic kidney disease; 3. Accorded with the diagnostic standard of deficiency of both qi and yin and blood stasis blocking collaterals in traditional Chinese medicine; 4. Sign the patient's informed consent form.

Exclusion criteria

Exclusion criteria: 1. Uncontrollable malignant hypertension; 2. Rapid deterioration of renal function recently; 3. Combined with serious primary diseases such as cardiovascular, liver, kidney and hematopoietic system, pregnancy; 4. History of adverse reactions to ARB drugs.

Design outcomes

Primary

Measure	Time frame
Urine protein to creatinine ratio;Superoxide dismutase;Malondialdehyde;	—

Secondary

Measure	Time frame
Urinary microparticles;24h urine protein quantification;Fasting blood sugar;Serum creatinine;HbA1c;	—

Countries

China

Contacts

Public ContactLiu Hongfang

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

lhfdoctor@126.com+86 13071176831

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026